Loading...

APC anti-mouse CD25 Antibody APC anti-mouse CD25 Antibody

Pricing & Availability
Clone
PC61 (See other available formats)
Regulatory Status
RUO
Other Names
IL-2Rα, Ly-43, p55, Tac
Isotype
Rat IgG1, λ
Ave. Rating
Submit a Review
Product Citations
publications
pc61
Con A-stimulated (3 days)splenocytes stained with PC61 APC
  • pc61
    Con A-stimulated (3 days)splenocytes stained with PC61 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
102012 100 µg NOK1287
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102011 25 µg NOK446
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD25 is a 55 kD glycoprotein also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Application References
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  2. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  3. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  4. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  5. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  6. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  7. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  8. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  9. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  10. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  11. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  12. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
  13. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  14. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  15. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  16. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  17. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  18. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  19. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  20. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  21. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  22. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
  23. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  24. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
  25. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
  26. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
  27. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  28. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  29. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  30. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  31. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
  32. Shi L, et al. 2021. Immunity. . PubMed
  33. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  34. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  35. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
  36. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
  37. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
  38. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  39. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
  40. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  41. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  42. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  43. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  44. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  45. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  46. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  47. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  48. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  49. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  50. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  51. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  52. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
  53. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  54. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  55. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  56. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
  57. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  58. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  59. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  60. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  61. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  62. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
  63. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  64. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  65. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  66. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  67. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  68. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
  69. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  70. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
  71. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  72. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  73. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  74. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  75. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  76. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  77. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  78. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  79. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  80. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  81. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  82. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  83. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  84. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  85. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  86. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  87. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
  88. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  89. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  90. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  91. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
  92. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  93. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  94. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  95. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  96. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  97. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  98. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  99. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  100. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  101. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  102. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  103. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  104. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  105. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  106. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  107. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  108. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  109. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  110. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  111. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
  112. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  113. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  114. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  115. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  116. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  117. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  118. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  119. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  120. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  121. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  122. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  123. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
  124. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  125. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  126. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  127. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  128. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  129. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  130. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  131. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  132. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  133. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
  134. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  135. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
  136. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
  137. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
  138. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  139. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  140. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  141. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  142. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
  143. Shi L, et al. 2021. Immunity. . PubMed
  144. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  145. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  146. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
  147. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
  148. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
  149. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  150. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
  151. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  152. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  153. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  154. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  155. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  156. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  157. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  158. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  159. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  160. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  161. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  162. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  163. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
  164. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  165. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  166. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  167. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
  168. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  169. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  170. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  171. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  172. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  173. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
  174. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  175. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  176. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  177. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  178. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  179. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
  180. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  181. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
  182. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  183. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  184. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  185. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  186. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  187. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  188. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  189. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  190. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  191. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  192. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  193. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  194. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  195. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  196. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  197. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  198. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
  199. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  200. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  201. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  202. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
  203. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  204. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  205. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  206. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  207. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  208. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  209. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  210. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  211. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  212. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  213. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  214. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  215. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  216. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  217. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  218. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  219. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  220. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  221. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  222. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
RRID
AB_312861 (BioLegend Cat. No. 102012)
AB_312860 (BioLegend Cat. No. 102011)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD25 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD25 PC61 FC
PE/Dazzle™ 594 anti-mouse CD25 PC61 FC
Brilliant Violet 711™ anti-mouse CD25 PC61 FC
Brilliant Violet 785™ anti-mouse CD25 PC61 FC
Alexa Fluor® 594 anti-mouse CD25 PC61 IHC-F
APC/Fire™ 750 anti-mouse CD25 PC61 FC
TotalSeq™-A0097 anti-mouse CD25 PC61 PG
KIRAVIA Blue 520™ anti-mouse CD25 PC61 FC
TotalSeq™-B0097 anti-mouse CD25 PC61 PG
TotalSeq™-C0097 anti-mouse CD25 PC61 PG
Spark NIR™ 685 anti-mouse CD25 Antibody PC61 FC
APC anti-mouse CD25 PC61 FC
Biotin anti-mouse CD25 PC61 FC
FITC anti-mouse CD25 PC61 FC
PE anti-mouse CD25 PC61 FC
PE/Cyanine5 anti-mouse CD25 PC61 FC
Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Alexa Fluor® 488 anti-mouse CD25 PC61 FC
Alexa Fluor® 647 anti-mouse CD25 PC61 FC
Pacific Blue™ anti-mouse CD25 PC61 FC
Alexa Fluor® 700 anti-mouse CD25 PC61 FC
APC/Cyanine7 anti-mouse CD25 PC61 FC
PerCP/Cyanine5.5 anti-mouse CD25 PC61 FC
PerCP anti-mouse CD25 PC61 FC
Brilliant Violet 421™ anti-mouse CD25 PC61 FC
Brilliant Violet 605™ anti-mouse CD25 PC61 FC
Brilliant Violet 650™ anti-mouse CD25 PC61 FC
Ultra-LEAF™ Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Brilliant Violet 510™ anti-mouse CD25 PC61 FC
PE/Fire™ 640 anti-mouse CD25 PC61 FC
Spark YG™ 581 anti-mouse CD25 PC61 FC
APC/Fire™ 810 anti-mouse CD25 PC61 FC
Brilliant Violet 750™ anti-mouse CD25 PC61 FC
PerCP/Fire™ 780 anti-mouse CD25 PC61 FC
PE/Fire™ 700 anti-mouse CD25 PC61 FC
Spark PLUS UV395™ anti-mouse CD25 PC61 FC
Spark Blue™ 574 anti-mouse CD25 (Flexi-Fluor™) PC61 FC
PerCP/Fire™ 806 anti-mouse CD25 Antibody PC61 FC
Spark PLUS B550™ anti-mouse CD25 PC61 FC
Spark YG™ 593 anti-mouse CD25 (Flexi-Fluor™) Antibody PC61 FC
Spark UV™ 387 anti-mouse CD25 (Flexi-Fluor™) PC61 FC
Spark PLUS V475™ anti-mouse CD25 Antibody PC61 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
PC61 (See other available formats)
Regulatory Status
RUO
Other Names
IL-2Rα, Ly-43, p55, Tac
Isotype
Rat IgG1, λ
Ave. Rating
Submit a Review
Product Citations
publications
pc61
Con A-stimulated (3 days)splenocytes stained with PC61 APC
  • pc61
    Con A-stimulated (3 days)splenocytes stained with PC61 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
102012 100 µg NOK1287
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102011 25 µg NOK446
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD25 is a 55 kD glycoprotein also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Application References
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  2. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  3. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  4. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  5. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  6. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  7. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  8. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  9. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  10. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  11. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  12. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
  13. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  14. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  15. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  16. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  17. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  18. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  19. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  20. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  21. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  22. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
  23. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  24. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
  25. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
  26. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
  27. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  28. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  29. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  30. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  31. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
  32. Shi L, et al. 2021. Immunity. . PubMed
  33. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  34. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  35. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
  36. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
  37. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
  38. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  39. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
  40. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  41. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  42. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  43. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  44. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  45. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  46. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  47. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  48. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  49. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  50. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  51. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  52. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
  53. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  54. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  55. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  56. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
  57. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  58. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  59. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  60. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  61. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  62. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
  63. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  64. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  65. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  66. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  67. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  68. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
  69. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  70. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
  71. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  72. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  73. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  74. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  75. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  76. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  77. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  78. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  79. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  80. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  81. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  82. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  83. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  84. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  85. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  86. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  87. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
  88. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  89. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  90. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  91. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
  92. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  93. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  94. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  95. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  96. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  97. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  98. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  99. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  100. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  101. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  102. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  103. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  104. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  105. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  106. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  107. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  108. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  109. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  110. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  111. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
  112. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  113. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  114. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  115. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  116. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  117. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  118. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  119. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  120. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  121. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  122. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  123. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
  124. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  125. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  126. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  127. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  128. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  129. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  130. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  131. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  132. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  133. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
  134. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  135. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
  136. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
  137. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
  138. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  139. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  140. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  141. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  142. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
  143. Shi L, et al. 2021. Immunity. . PubMed
  144. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  145. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  146. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
  147. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
  148. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
  149. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  150. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
  151. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  152. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  153. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  154. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  155. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  156. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  157. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  158. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  159. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  160. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  161. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  162. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  163. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
  164. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  165. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  166. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  167. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
  168. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  169. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  170. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  171. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  172. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  173. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
  174. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  175. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  176. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  177. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  178. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  179. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
  180. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  181. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
  182. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  183. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  184. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  185. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  186. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  187. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  188. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  189. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  190. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  191. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  192. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  193. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  194. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  195. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  196. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  197. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  198. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
  199. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  200. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  201. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  202. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
  203. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  204. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  205. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  206. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  207. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  208. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  209. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  210. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  211. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  212. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  213. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  214. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  215. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  216. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  217. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  218. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  219. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  220. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  221. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  222. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
RRID
AB_312861 (BioLegend Cat. No. 102012)
AB_312860 (BioLegend Cat. No. 102011)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

Other Formats

View All CD25 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD25 PC61 FC
PE/Dazzle™ 594 anti-mouse CD25 PC61 FC
Brilliant Violet 711™ anti-mouse CD25 PC61 FC
Brilliant Violet 785™ anti-mouse CD25 PC61 FC
Alexa Fluor® 594 anti-mouse CD25 PC61 IHC-F
APC/Fire™ 750 anti-mouse CD25 PC61 FC
TotalSeq™-A0097 anti-mouse CD25 PC61 PG
KIRAVIA Blue 520™ anti-mouse CD25 PC61 FC
TotalSeq™-B0097 anti-mouse CD25 PC61 PG
TotalSeq™-C0097 anti-mouse CD25 PC61 PG
Spark NIR™ 685 anti-mouse CD25 Antibody PC61 FC
APC anti-mouse CD25 PC61 FC
Biotin anti-mouse CD25 PC61 FC
FITC anti-mouse CD25 PC61 FC
PE anti-mouse CD25 PC61 FC
PE/Cyanine5 anti-mouse CD25 PC61 FC
Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Alexa Fluor® 488 anti-mouse CD25 PC61 FC
Alexa Fluor® 647 anti-mouse CD25 PC61 FC
Pacific Blue™ anti-mouse CD25 PC61 FC
Alexa Fluor® 700 anti-mouse CD25 PC61 FC
APC/Cyanine7 anti-mouse CD25 PC61 FC
PerCP/Cyanine5.5 anti-mouse CD25 PC61 FC
PerCP anti-mouse CD25 PC61 FC
Brilliant Violet 421™ anti-mouse CD25 PC61 FC
Brilliant Violet 605™ anti-mouse CD25 PC61 FC
Brilliant Violet 650™ anti-mouse CD25 PC61 FC
Ultra-LEAF™ Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Brilliant Violet 510™ anti-mouse CD25 PC61 FC
PE/Fire™ 640 anti-mouse CD25 PC61 FC
Spark YG™ 581 anti-mouse CD25 PC61 FC
APC/Fire™ 810 anti-mouse CD25 PC61 FC
Brilliant Violet 750™ anti-mouse CD25 PC61 FC
PerCP/Fire™ 780 anti-mouse CD25 PC61 FC
PE/Fire™ 700 anti-mouse CD25 PC61 FC
Spark PLUS UV395™ anti-mouse CD25 PC61 FC
Spark Blue™ 574 anti-mouse CD25 (Flexi-Fluor™) PC61 FC
PerCP/Fire™ 806 anti-mouse CD25 Antibody PC61 FC
Spark PLUS B550™ anti-mouse CD25 PC61 FC
Spark YG™ 593 anti-mouse CD25 (Flexi-Fluor™) Antibody PC61 FC
Spark UV™ 387 anti-mouse CD25 (Flexi-Fluor™) PC61 FC
Spark PLUS V475™ anti-mouse CD25 Antibody PC61 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account